Limits...
Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders.

Lee SH, Kim BK, Oh J, Park JS, Lee DJ, Lee HC, Kim JH, Hong MK - Korean Circ J (2013)

Bottom Line: Stent thrombosis is a very serious problem after drug-eluting stent (DES) implantation even though its incidence is about or less than 1%.As the clopidogrel resistance is expected to play an important role in the occurrence of stent thrombosis, new anti-platelet agents overcoming this issue can give us another choice.We experienced a case of a 58-year-old male with successful prasugrel rescue therapy in a patient with clopidogrel resistance who had recurrent stent thrombosis following DES implantation.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT
Stent thrombosis is a very serious problem after drug-eluting stent (DES) implantation even though its incidence is about or less than 1%. As the clopidogrel resistance is expected to play an important role in the occurrence of stent thrombosis, new anti-platelet agents overcoming this issue can give us another choice. We experienced a case of a 58-year-old male with successful prasugrel rescue therapy in a patient with clopidogrel resistance who had recurrent stent thrombosis following DES implantation.

No MeSH data available.


Related in: MedlinePlus

The nine-month follow-up coronary angiography with prasugrel showed good patency of previous stent at mid portion of the left anterior descending artery (black arrow) and distal portion of left circumflex artery (white arrow) lesion without thrombus.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3675310&req=5

Figure 3: The nine-month follow-up coronary angiography with prasugrel showed good patency of previous stent at mid portion of the left anterior descending artery (black arrow) and distal portion of left circumflex artery (white arrow) lesion without thrombus.

Mentions: Finally, clopidogrel was switched with prasugrel 10 mg daily followed by a 60 mg loading. Six days later, the platelet function test showed an adequate platelet inhibition (9 PRU, 98% inhibition). After discharge, cilostazol was discontinued on May 2011 (4-month use) and the platelet function test still showed a good response to the dual antiplatelet with aspirin and prasugrel (92 PRU, 70% inhibition). After a nine-month follow-up, the coronary angiography showed a patent both in LAD and LCx stents. Currently, dual antiplatelet drugs with aspirin and prasugrel were maintained without any chest pain (13-month use) (Fig. 3).


Successful prasugrel rescue therapy in clopidogrel resistant patients who had recurrent stent thrombosis of drug-eluting-stent: the role of prasugrel in clopidogrel nonresponders.

Lee SH, Kim BK, Oh J, Park JS, Lee DJ, Lee HC, Kim JH, Hong MK - Korean Circ J (2013)

The nine-month follow-up coronary angiography with prasugrel showed good patency of previous stent at mid portion of the left anterior descending artery (black arrow) and distal portion of left circumflex artery (white arrow) lesion without thrombus.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3675310&req=5

Figure 3: The nine-month follow-up coronary angiography with prasugrel showed good patency of previous stent at mid portion of the left anterior descending artery (black arrow) and distal portion of left circumflex artery (white arrow) lesion without thrombus.
Mentions: Finally, clopidogrel was switched with prasugrel 10 mg daily followed by a 60 mg loading. Six days later, the platelet function test showed an adequate platelet inhibition (9 PRU, 98% inhibition). After discharge, cilostazol was discontinued on May 2011 (4-month use) and the platelet function test still showed a good response to the dual antiplatelet with aspirin and prasugrel (92 PRU, 70% inhibition). After a nine-month follow-up, the coronary angiography showed a patent both in LAD and LCx stents. Currently, dual antiplatelet drugs with aspirin and prasugrel were maintained without any chest pain (13-month use) (Fig. 3).

Bottom Line: Stent thrombosis is a very serious problem after drug-eluting stent (DES) implantation even though its incidence is about or less than 1%.As the clopidogrel resistance is expected to play an important role in the occurrence of stent thrombosis, new anti-platelet agents overcoming this issue can give us another choice.We experienced a case of a 58-year-old male with successful prasugrel rescue therapy in a patient with clopidogrel resistance who had recurrent stent thrombosis following DES implantation.

View Article: PubMed Central - PubMed

Affiliation: Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea.

ABSTRACT
Stent thrombosis is a very serious problem after drug-eluting stent (DES) implantation even though its incidence is about or less than 1%. As the clopidogrel resistance is expected to play an important role in the occurrence of stent thrombosis, new anti-platelet agents overcoming this issue can give us another choice. We experienced a case of a 58-year-old male with successful prasugrel rescue therapy in a patient with clopidogrel resistance who had recurrent stent thrombosis following DES implantation.

No MeSH data available.


Related in: MedlinePlus